Side-by-side · Research reference
5-Amino-1MQvsThymalin
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongDraft8/38 cited
BHuman-MechanisticDraft12/40 cited
5-Amino-1MQ
NNMT inhibitor · Methylation / SAM modulation
Oral · Once daily fasted
Thymalin
Immune restorer · Russian peptide bioregulator
IM · Daily for 5–10 days · 1-2×/year
01Mechanism of Action
Parameter
5-Amino-1MQ
Thymalin
Primary target
Nicotinamide N-methyltransferase (NNMT)Neelakantan 2018
T-cell precursors + thymus-axis maturation pathwayKhavinson 2002
Pathway
NNMT inhibition → preserved cellular SAM + NAD⁺ → restored methylation balance + ↑ thermogenic gene expressionNeelakantan 2018
Modulation of T-cell differentiation + thymic hormone restoration in age-involuted thymusKhavinson 2002
Downstream effect
Reversal of HFD-induced obesity in murine models; improved metabolic profileNeelakantan 2018
Restored T-cell populations, improved immune surveillance, reduced infection rates in elderlyKhavinson 2002
Feedback intact?
—
—
Origin
Selective small-molecule inhibitor designed in academic medicinal chemistry programsNeelakantan 2018
Polypeptide fraction isolated from calf thymus extractKhavinson 2002
Antibody development
—
—
02Dosage Protocols
Parameter
5-Amino-1MQ
Thymalin
Standard dose
100–200 mg / day oralNeelakantan 2018
Anecdotal community range; murine doses scaled.
5–10 mg / day IM × 5–10 daysKhavinson 2002
Frequency
Once daily, fasted
Once daily during cycle
Lower / starter dose
50 mg / day
2.5 mg / day
Evidence basis
Animal-strong; no human RCT dataNeelakantan 2018
Russian clinical + in vitroKhavinson 2002
Duration
8–12 weeks per cycle
5–10 day cycles, 1–2× per year
Form
Oral capsule
—
Timing
Morning fasted preferred
Morning preferred
Half-life
Hours (estimated; no human PK published)
Hours (estimated)
Reconstitution
—
Saline or bacteriostatic water
04Side Effects & Safety
Parameter
5-Amino-1MQ
Thymalin
GI symptoms
Mild nausea (anecdotal)
—
Methylation disruption
Theoretical risk if NNMT is over-inhibited (B vitamin metabolism)
—
Long-term safety
Unknown — no human trials
Limited Western data
Cancer risk
Unclear — NNMT also studied in oncology contexts
—
Pregnancy / OB
Avoid
Avoid
Drug interactions
Theoretical with niacin / B-vitamin supplements
—
Injection site reaction
—
Mild erythema at IM site
Allergic reaction
—
Rare hypersensitivity to bovine-derived polypeptide
Autoimmune flare
—
Theoretical risk in active autoimmune disease
Absolute Contraindications
5-Amino-1MQ
- ·Pregnancy / breastfeeding
- ·Active malignancy
Thymalin
- ·Pregnancy / breastfeeding
- ·Bovine protein hypersensitivity
Relative Contraindications
5-Amino-1MQ
- ·Methylation-sensitive conditions (MTHFR mutation)
- ·Concurrent niacin / NAD+ precursor supplementation (theoretical interference)
Thymalin
- ·Active autoimmune disease
- ·Concurrent immunosuppressant therapy
05Administration Protocol
Parameter
5-Amino-1MQ
Thymalin
1. Form
Oral capsule. No injection.
Add 1–2 mL saline or bacteriostatic water per 10 mg vial.
2. Administration
Take with water, fasted preferred.
Intramuscular — deltoid or gluteal. Rotate sites.
3. Timing
Morning fasted.
Morning preferred during cycle.
4. Storage
Room temp ≤25 °C, dry place.
Lyophilised: refrigerate, light-protected. Reconstituted: use immediately.
5. Caveat
Monitor B-vitamin status with chronic use.
23–25G, 25–38 mm IM needle.
06Stack Synergy
5-Amino-1MQ
— no documented stacks
Thymalin
+ Thymosin α-1
ModerateThymalin is a polypeptide complex; Thymosin α-1 is a single purified peptide. Both target the thymus-axis but at different levels — Thymalin restores broad thymic signaling; Tα-1 provides a specific molecular activator. Anecdotally combined for elderly immune support.
- Thymalin
- 5–10 mg IM · daily × 7 days
- Thymosin α-1
- 1.6 mg SQ · 2× weekly during the cycle
- Primary benefit
- Broad thymic restoration + targeted immune activation